Comparison of ticrynafen and probenecid in patients with elevated uric acid levels.

Article Details

Citation

Copy to clipboard

Jain AK, Ryan JR, McMahon FG

Comparison of ticrynafen and probenecid in patients with elevated uric acid levels.

Nephron. 1979;23 Suppl 1:46-50.

PubMed ID

381955 [ View in PubMed

]

Abstract

Ticrynafen, 125--250 mg/day was compared with probenecid 0.5--1.0 g/day in patients with elevated serum uric acid values in a randomized, double-blind crossover study. Each treatment period lasted 12 weeks. The mean reduction in serum uric acid from 9.4 +/- 1.2 to 6.22 +/- 1.2 mg/dl (33.8%) during ticrynafen was greater (p less than 0.01) than that from 9.46 +/- 1.1 to 7.0 +/- 1.3 mg/dl (26%) during probenecid treatment. There were slight increases in serum creatinine and BUN and decreases in body weight during ticrynafen treatment. There were no statistically significant changes in serum electrolytes. The hypouricemic effect of ticrynafen was well maintained during its subsequent open-label administration for 18 months without any deterioration of renal function.

DrugBank Data that Cites this Article

Pharmaco-metabolomics

Drug	Drug Groups	Metabolite	Change	Description
Tienilic acid	Withdrawn	Uric acid	decreased	Tienilic acid decreases the level of Uric acid in the blood
Tienilic acid	Withdrawn	Creatinine	increased	Tienilic acid increases the level of Creatinine in the blood
Tienilic acid	Withdrawn	Blood urea nitrogen	increased	Tienilic acid increases the level of Blood urea nitrogen in the blood